The ACIP decision comes two months after the FDA expanded its label for the meningococcal vaccine. Menveo is now cleared for use in babies aged two months and older, and ACIP has recommended use in infants up to the age of 23 months, but only in certain instances.
Bringing a new vaccine to market in Europe is tough. After winning approval at the European level, manufacturers must show the value of the product to national decision makers. Novartis is in the middle of this process with its meningitis B vaccine, and still has a long way to go.
A team from Australia has shown positive immune responses in a Phase II trial of Pfizer's meningitis B vaccine in teenagers.